Oct 7 (Reuters) - BillionToOne filed for an initial

public offering in the United States on Tuesday.

The company's filing comes at a time when U.S. IPO activity

is picking up, reversing a slowdown from earlier in the year,

when trade-policy uncertainty curbed momentum.

The Menlo Park, California-based precision diagnostics

company will list on the Nasdaq under the "BLLN" ticker symbol.

BillionToOne develops molecular diagnostic tests - including

a non-invasive prenatal screen and liquid biopsy - for diseases.

It reported revenue of $125.5 million in the first half of

2025, compared with $69 million in the year-ago period,

according to the IPO filing.

Net loss narrowed to $4.2 million in the six months ended

June 30, from a loss of $15.2 million in the same period last

year.

J.P. Morgan, Wells Fargo and William Blair are among the

underwriters for the offering.